Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 2/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.61 |
| ▸ | CCNC | P24863 | 1/20 | 0.58 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.57 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.57 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.57 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL378881 | 0.89 | CDK8 (0.63) | CDK8MAPK14CCNCMAPK13MAPK12 | |
| SCHEMBL12216015 | 0.88 | CDK8 (0.69) | CDK8MAPK14CCNCMAPK13MAPK12 | |
| SCHEMBL12256427 | 0.87 | CDK8 (0.67) | CDK8MAPK14CCNCMAPK13MAPK12 | |
| SCHEMBL26936743 | 0.86 | CDK8 (0.66) | CDK8MAPK14CCNCMAPK13MAPK12 | |
| SCHEMBL3174282 | 0.84 | CDK8 (0.52) | CDK8MAPK14CCNCMAPK13MAPK12 | |
| SCHEMBL3174427 | 0.83 | CDK8 (0.53) | CDK8MAPK14CCNCMAPK13MAPK12 | |
| SCHEMBL3390231 | 0.83 | CDK8 (0.50) | CDK8MAPK14CCNCMAPK13MAPK12 | |
| SCHEMBL3181946 | 0.82 | CDK8 (0.52) | CDK8MAPK14CCNCMAPK13MAPK12 | |
| SCHEMBL2446678 | 0.82 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1600309 | 0.81 | CDK8 (0.82) | CDK8MAPK14CCNCMAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1997809-B1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8518983-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-1997810-B1 | Indazoles, benzotriazoles and N-analogs thereof as p38 kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2039685-B1 | Heterobicyclic compounds as P38 inhibitors | ARRAY BIOPHARMA INC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8017641-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-7799782-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090149459-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090143422-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090136596-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-7521447-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-2039685-A2 | Heterobicyclic compounds as P38 inhibitors | Array Biopharma, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-1997809-A2 | Indazole, benzoxazole and pyrazolopyridine derivatives for medical use | Array Biopharma Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997810-A2 | Indazole, benzoxazole and pyrazolopyridine derivatives for medical use | Array Biopharma Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997811-A2 | Indazole, benzoxazole and pyrazolopyridine derivatives as P38 kinase inhibitors | Array Biopharma Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2004078116-A9 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2008-09-12 | — | — | WO | disclosed |
| EP-1606283-A4 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1606283-A2 | P38 INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. | 2004-09-30 | — | — | US | disclosed |
| US-20040180896-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA, INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004078116-A2 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143422-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | MAPKAPK2, MAPK1, MAPK8 | CDK8 285/4885MAPK14 37/4885CCNC 1645/4885 |
| US-20090136596-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | MAPKAPK2, MAPK1, MAPK8 | CDK8 285/4885MAPK14 37/4885CCNC 1645/4885 |
| US-20090149459-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | MAPKAPK2, MAPK1, MAPK8 | CDK8 285/4885MAPK14 37/4885CCNC 1645/4885 |
| US-20040180896-A1 | P38 inhibitors and methods of use thereof | MAPK1, MAPK3, MAPK8 | CDK8 284/4885MAPK14 39/4885CCNC 1497/4885 |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | MAPK1, MAPK3, MAPK8 | CDK8 284/4885MAPK14 39/4885CCNC 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.